Challenges in polymer therapeutics: State of the art and prospects of polymer drugs

Advances in Experimental Medicine and Biology

Volumn 519, Issue , 2003, Pages 1-27

  Kabanov, Alexander V ^a   Okano, Teruo ^b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MACROGOL; N (2 HYDROXYPROPYL)METHACRYLAMIDE; POLOXAMER; POLYMER; POVIDONE;

BIODEGRADABILITY; CONFERENCE PAPER; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG TARGETING; GENE DELIVERY SYSTEM; PHARMACEUTICS; PRIORITY JOURNAL;

EID: 0038294679     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: None     Document Type: Conference Paper

References (160)

1. Langer, R., 1998, Drug delivery and targeting. Nature 392:5-10.
2. Northfelt, D. W., B. J. Dezube, J. A. Thommes, B. J. Miller, M. A. Fischl, A. Friedman-Kien, L. D. Kaplan, C. Du Mond, R. D. Mamelok and D. H. Henry, 1998, Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J. Clin. Oncol. 16:2445-2451.
3. Rosenblum, M. G. and G. N. Hortobagyi, 1986, Pharmacokinetics and tissue disposition of the biological response modifier BAY i 7433 (copovithane) in patients with cancer. Cancer Chemother. Pharmacol. 18:247-251.
4. Duncan, R., S. Gac-Breton, R. Keane, R. Musila, Y. N. Sat, R. Satchi and F. Searle, 2001, Polymer-drug conjugates, PDEPT and PELT: basic principles for design and transfer from the laboratory to clinic. J. Control. Release 74:135-146.
5. Kabanov, A. V. and V. Alakhov, 2002, Pluronic block copolymers in drug delivery: From micellar nanocontainers to biological response modifiers. Cr Rev Ther Dr Targ 19:1-73.
6. Maynard, C., R. Swenson, J. A. Paris, J. S. Martin, A. P. Hallstrom, M. D. Cerqueira and W. D. Weaver, 1998, Randomized, controlled trial of RheothRx (poloxamer 188) in patients with suspected acute myocardial infarction. RheothRx in Myocardial Infarction Study Group. Am Heart J 135:797-804.
7. Fournier, C., B. Hecquet, P. Bouffard, M. Vert, A. Caty, M. O. Vilain, L. Vanseymortier, S. Merle, A. Krikorian, J. L. Lefebvre and et al., 1991, Experimental studies and preliminary clinical trial of vinorelbine- loaded polymeric bioresorbable implants for the local treatment of solid tumors. Cancer Res 51:5384-5391.
8. Einmahl, S., S. Capancioni, K. Schwach-Abdellaoui, M. Moeller, F. Behar-Cohen and R. Gurny, 2001, Therapeutic applications of viscous and injectable poly(ortho esters). Adv. Drug Deliv. Rev. 53:45-73.
9. Kattan, J., J. P. Droz, P. Couvreur, J. P. Marino, A. Boutan-Laroze, P. Rougier, P. Brault, H. Vranckx, J. M. Grognet, X. Morge and et al., 1992, Phase I clinical trial and pharmacokinetic evaluation of doxorubicin carried by polyisohexylcyanoacrylate nanoparticles. Invest New Drugs 10:191-199.
10. Seymour, L. W., S. P. Olliff, C. J. Poole, P. G. De Takats, R. Orme, D. R. Ferry, H. Maeda, T. Konno and D. J. Kerr, 1998, A novel dosage approach for evaluation of SMANCS [poly-(styrene-co- maleyl-half-n-butylate) - neocarzinostatin] in the treatment of primary hepatocellular carcinoma. Int. J. Oncol. 12:1217-1223.
11. Maeda, H., 2001, SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv. Drug Deliv. Rev. 46:169-185.
12. Ardizzone, S., M. Petrillo, P. Molteni, S. Desideri and G. Bianchi Porro, 1995, Coated oral 5-aminosalicylic acid (Claversal) is equivalent to sulfasalazine for remission maintenance in ulcerative colitis. A double- blind study. J. Clin. Gastroenterol. 21:287-289.
13. Schenk, J. F., P. Radziwon, S. Morsdorf, P. Eckenberger and H. K. Breddin, 1999, Effects of aprosulate, a novel synthetic glycosaminoglycan, on coagulation and platelet function parameters: a prospective, randomized phase I study. Clin. Appl. Thromb. Hemost. 5:192-197.
14. Payne, L. G., S. A. Jenkins, A. L. Woods, E. M. Grund, W. E. Geribo, J. R. Loebelenz, A. K. Andrianov and B. E. Roberts, 1998, Poly[di(carboxylatophenoxy)phosphazene] (PCPP) is a potent immunoadjuvant for an influenza vaccine. Vaccine 16:92-98.
15. Payne, L. G., S. A. Jenkins, A. Andrianov and B. E. Roberts, 1995, Water-soluble phosphazene polymers for parenteral and mucosal vaccine delivery. Pharm Biotechnol 6:473-493.
16. Andrianov, A. K., J. Chen and L. G. Payne, 1998, Preparation of hydrogel microspheres by coacervation of aqueous polyphosphazene solutions. Biomaterials 19:109-115.
17. Payne, L. G. and A. K. Andrianov, 1998, Protein release from polyphosphazene matrices. Adv Drug Deliv Rev 31:185-196.
18. Song, J., C. H. Suh, Y. B. Park, S. H. Lee, N. C. Yoo, J. D. Lee, K. H. Kim and S. K. Lee, 2001, A phase I/IIa study on intra-articular injection of holmium-166-chitosan complex for the treatment of knee synovitis of rheumatoid arthritis. Eur. J. Nucl. Med. 28:489-497.
19. Pittler, M. H., N. C. Abbot, E. F. Harkness and E. Ernst, 1999, Randomized, double-blind trial of chitosan for body weight reduction. Eur. J. Clin. Nutr. 53:379-381.
20. Nekrasov, A. V., N. G. Puchkova, R. I. Attaullakhanov, R. V. Petrov and A. S. Ivanova, 1996, Compounds having immunostimulating activity and methods of use thereof., 5503830
21. El'shina, G. A., M. A. Gorbunov, T. A. Bektimirov, N. I. Lonskaia, L. I. Pavlova, A. A. Nikul'shin, R. M. Khaitov, A. V. Nekrasov, A. S. Ivanova, M. N. Matrosovich and N. G. Puchkova, 2000, [The evaluation of the reactogenicity, harmlessness and prophylactic efficacy of Grippol trivalent polymer-subunit influenza vaccine administered to schoolchildren]. Zh. Mikrobiol. Epidemiol. Immunobiol.:50-54.
22. Kataoka, K., A. Harada and Y. Nagasaki, 2001, Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv Drug Deliv Rev 47:113-131.
23. Katayose, S. and K. Kataoka, 1997, Water-soluble polyion complex associates of DNA and poly(ethylene glycol)-poly(L-lysine) block copolymer. Bioconj. Chem. 8:702-707.
24. Kwon, G. S. and K. Kataoka, 1995, Block copolymer micelles as long-circulating drug vehicles. Adv. Drug Delivery Rev. 16:295-309.
25. Yokoyama, M., M. Miyauchi, N. Yamada, T. Okano, Y. Sakurai, K. Kataoka and S. Inoue, 1990, Characterization and anticancer activity of the micelle-forming polymeric anticancer drug adriamycin-conjugated poly(ethylene glycol)-poly(aspartic acid) block copolymer. Cancer Res. 50:1693-1700.
26. Seymour, L., K. Kataoka and A. Kabanov, 1998, Cationic block copolymers as self-assembling vectors for gene delivery, In Self-assembling Complexes for Gene Delivery. From Laboratory to Clinical Trial (A. Kabanov, P. Felgner and L. Seymour eds), John Wiley & Sons, Chichester, UK pp 219-239.
27. Harada, A. and K. Kataoka, 1997, Formation of stable and monodispersive polyion complex micelles in aqueous medium from poly(L-lysine) and poly(ethylene glycol)poly(aspartic acid) block copolymer. J. Macromol. Sci., Pure Appl. Chem. A34:2119-2133.
28. Harada, A. and K. Kataoka, 1998, Novel polyion complex micelles entrapping enzyme molecules in the core: preparation of narrowly-distributed micelles from lysozyme and poly(ethylene glycol)-poly(aspartic acid) block copolymer in aqueous medium. Macromolecules 31:288-294.
29. Harada, A. and K. Kataoka, 1999, Chain length recognition: core-shell supramolecular assembly from oppositely charged block copolymers. Science 283:65-67.
30. Harada, A. and K. Kataoka, 1999, On-Off control of enzymatic activity synchronizing with reversible formation of supramolecular assembly from enzyme and charged block copolymers. J. Am. Chem. Soc. 121:9241-9242.
31. Harada, A. and K. Kataoka, 1999, Novel polyion complex micelles entrapping enzyme molecules in the core. 2. Characterization of the micelles prepared at nonstoichiometric mixing ratios. Langmuir 15:4208-4212.
32. Harada, A., H. Togawa and K. Kataoka, 2001, Physicochemical properties and nuclease resistance of antisense- oligodeoxynucleotides entrapped in the core of polyion complex micelles composed of poly(ethylene glycol)-poly(L-Lysine) block copolymers. Eur. J. Pharm. Sci. 13:35-42.
33. Dash, P. R., V. Toncheva, E. Schacht and L. W. Seymour, 1997, Synthetic polymers for vectorial delivery of DNA: characterization of polymer-DNA complexes by photon correlation spectroscopy and stability to nuclease degradation and disruption by polyanions in vitro. J. Controlled Release 48:269-276.
34. Dekie, L., V. Toncheva, P. Dubruel, E. H. Schacht, L. Barrett and L. W. Seymour, 2000, Poly-L-glutamic acid derivatives as vectors for gene therapy. J Control Release 65:187-202.
35. Oupicky, D., C. Konak, K. Ulbrich, M. A. Wolfert and L. W. Seymour, 2000, DNA delivery systems based on complexes of DNA with synthetic polycations and their copolymers. J Control Release 65:149-171.
36. Read, M. L., T. Etrych, K. Ulbrich and L. W. Seymour, 1999, Characterisation of the binding interaction between poly(L-lysine) and DNA using the fluorescamine assay in the preparation of non-viral gene delivery vectors. FEBS Lett 461:96-100.
37. Benns, J. M., J. S. Choi, R. I. Mahato, J. S. Park and S. W. Kim, 2000, pH-sensitive cationic polymer gene delivery vehicle: N-Ac-poly(L- histidine)-graft-poly(L-lysine) comb shaped polymer. Bioconjug. Chem. 11:637-645.
38. Choi, Y. H., F. Liu, J.-S. Kim, Y. K. Choi, J. S. Park and S. W. Kim, 1998, Polyethylene glycol-grafted poly-L-lysine as polymeric gene carrier. J. Contr. Release 54:39-48.
39. Choi, Y. H., F. Liu, J. S. Park and S. W. Kim, 1998, Lactose-poly(ethylene glycol)-grafted poly-L-lysine as hepatoma cell- tapgeted gene carrier. Bioconjug Chem 9:708-718.
40. Choi, Y. H., F. Liu, J. S. Choi, S. W. Kim and J. S. Park, 1999, Characterization of a targeted gene carrier, lactose-polyethylene glycol-grafted poly-L-lysine and its complex with plasmid DNA. Hum Gene Ther 10:2657-65.
41. Allen, C., D. Maysinger and A. Eisenberg, 1999, Nano-engineering block copolymer aggregates for drug delivery. Coll. Surfaces, B: Biointerfaces 16:3-27.
42. Kabanov, A. V., V. P. Chekhonin, V. Y. Alakhov, E. V. Batrakova, A. S. Lebedev, N. S. Melik-Nubarov, S. A. Arzhakov, A. V. Levashov, G. V. Morozov, E. S. Severin and V. A. Kabanov, 1989, The neuroleptic activity of haloperidol increases after its solubilization in surfactant micelles. Micelles as microcontainers for drug targeting. FEBS Lett. 258:343-345.
43. Kabanov, A. V., S. V. Vinogradov, Y. G. Suzdaltseva and V. Y. Alakhov, 1995, Water-soluble block polycations as carriers for oligonucleotide delivery. Bioconjug. Chem. 6:639-643.
44. Kabanov, A. V., 1999, Taking polycation gene delivery systems from in vitro to in vivo. Pharm. Sci. Tech. Today 2:365-372.
45. Vinogradov, S. V., T. K. Bronich and A. V. Kabanov, 1998, Self-assembly of polyaminepoly(ethylene glycol) copolymers with phosphorothioate oligonucleotides. Bioconjug. Chem. 9:805-812.
46. Nguyen, H. K., P. Lemieux, S. V. Vinogradov, C. L. Gebhart, N. Guerin, G. Paradis, T. K. Bronich, V. Y. Alakhov and A. V. Kabanov, 2000, Evaluation of polyetherpolyethyleneimine graft copolymers as gene transfer agents. Gene Ther 7:126-138.
47. Gebhart, C. L. and A. V. Kabanov, 2001, Evaluation of polyplexes as gene transfer agents. J. Contr. Release 73:401-416.
48. Fraser, J. R., T. C. Laurent, H. Pertoft and E. Baxter, 1981, Plasma clearance, tissue distribution and metabolism of hyaluronic acid injected intravenously in the rabbit. Biochem J 200:415-424.
49. Kissel, M., P. Peschke, V. Subr, K. Ulbrich, J. Schuhmacher, J. Debus and E. Friedrich, 2001, Synthetic macromolecular drug carriers: biodistribution of poly[(N-2-hydroxypropyl)methacrylamide] copolymers and their accumulation in solid rat tumors. PDA J Pharm Sci Technol 55:191-201.
50. Jewell, R. C., S. P. Khor, D. F. Kisor, K. A. LaCroix and W. A. Wargin, 1997, Pharmacokinetics of RheothRx injection in healthy male volunteers. J. Pharm. Sci. 86:808-812.
51. Mitra, G., S. Mumtaz and B. K. Bachhawat, 1993, Enhanced stability and therapeutic utility of proteins upon conjugation with hydrophilic polymers. Hindustan Antibiot Bull 35:133-156.
52. Hoste, K., E. Schacht and L. Seymour, 2000, New derivatives of polyglutamic acid as drug carrier systems. J Control Release 64:53-61.
53. Douglas, S. J., S. S. Davis and L. Illum, 1987, Nanoparticles in drug delivery. Crit Rev Ther Drug Carrier Syst 3:233-261.
54. Jung, T., W. Kamm, A. Breitenbach, E. Kaiserling, J. X. Xiao and T. Kissel, 2000, Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake? Eur J Pharm Biopharm 50:147-160.
55. Darney, P. D., 1994, Hormonal implants: contraception for a new century. Am J Obstet Gynecol 170:1536-43.
56. Rothen-Weinhold, A., K. Besseghir, Y. De Zelicourt and R. Gurny, 1998, Development and evaluation in vivo of a long-term delivery system for vapreotide, a somatostatin analogue. J Control Release 52:205-213.
57. Petrov, R. V., R. M. Khaitov, A. A. Mikhailova, V. M. Manko and V. A. Kabanov, 1984, Cell interactions and vaccines of tomorrow. Mir publishers, Moscow.
58. Maheshwari, A., R. I. Mahato, J. McGregor, S. Han, W. E. Samlowski, J. S. Park and S. W. Kim, 2000, Soluble biodegradable polymer-based cytokine gene delivery for cancer treatment. Mol. Ther. 2:121-130.
59. Koh, J. J., K. S. Ko, M. Lee, S. Han, J. S. Park and S. W. Kim, 2000, Degradable polymeric carrier for the delivery of IL-10 plasmid DNA to prevent autoimmune insulitis of NOD mice. Gene Ther. 7:2099-2104.
60. Ko, K. S., M. Lee, J. J. Koh and S. W. Kim, 2001, Combined administration of plasmids encoding IL-4 and IL-10 prevents the development of autoimmune diabetes in nonobese diabetic mice. Mol Ther 4:313-316.
61. Thorpe, P. E. and F. J. Burrows, 1995, Antibody-directed targeting of the vasculature of solid tumors. Breast Cancer Res Treat 36:237-251.
62. Goodwin, D. A. and C. F. Meares, 1999, Pretargeted peptide imaging and therapy. Cancer Biother Radiopharm 14:145-152.
63. Torchilin, V. P., 1998, In vitro and in vivo availability of liposomes, In Self-assembling complexes for gene delivery: From laboratory to clinical trial (A. V. Kabanov, P. L. Felgner and L. W. Seymour eds), John Wiley, Chichester, New York, Weinheim, Brisbane, Singapore, Toronto pp 277-293.
64. Poste, G., C. Bucana, A. Raz, P. Bugelski, R. Kirsh and I. J. Fidler, 1983, Site-specific (targeted) drug delivery in cancer therapy. Biotech 1:869-868.
65. Judson, I., J. A. Radford, M. Harris, J. Y. Blay, Q. van Hoesel, A. le Cesne, A. T. van Oosterom, M. J. Clemons, C. Kamby, C. Hermans, J. Whittaker, E. Donato di Paola, J. Verweij and S. Nielsen, 2001, Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 37:870-877.
66. Shi, N. and W. M. Pardridge, 2000, Noninvasive gene targeting to the brain. Proc Natl Acad Sci USA 97:7567-7572.
67. Torchilin, V. P., 2000, Drug targeting. Eur J Pharm Sci 11 Suppl 2:S81-S91.
68. Yokoyama, M., T. Okano, Y. Sakurai, K. Kataoka and S. Inoue, 1989, Stabilization of disulfide linkage in drug-polymer-immunoglobulin conjugate by microenvironmental control. Biochem. Biophys. Res. Commun. 164:1234-1239.
69. Khaw, B. A., J. daSilva, I. Vural, J. Narula and V. P. Torchilin, 2001, Intracytoplasmic gene delivery for in vitro transfection with cytoskeleton-specific immunoliposomes. J Control Release 75:199-210.
70. Vinogradov, S., E. Batrakova, S. Li and A. Kabanov, 1999, Polyion Complex Micelles with Protein-Modified Corona for Receptor-Mediated Delivery of Oligonucleotides into Cells. Bioconjug. Chem. 10:851-860.
71. Lubbe, A. S., C. Alexiou and C. Bergemann, 2001, Clinical applications of magnetic drug targeting. J Surg Res 95:200-206.
72. Rudge, S., C. Peterson, C. Vessely, J. Koda, S. Stevens and L. Catterall, 2001, Adsorption and desorption of chemotherapeutic drugs from a magnetically targeted carrier (MTC). J Control Release 74:335-340.
73. Maeda, H., T. Sawa and T. Konno, 2001, Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J Control Release 74:47-61.
74. Maeda, H., 2001, The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 41:189-207.
75. Duncan, R., 1999, Polymer conjugates for tumour targeting and intracytoplasmic delivery. The EPR effect as a common gateway? Pharm. Sci. Technol. Today. 2:441-449.
76. Noguchi, Y., J. Wu, R. Duncan, J. Strohalm, K. Ulbrich, T. Akaike and H. Maeda, 1998, Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jpn J Cancer Res 89:307-314.
77. Malik, N., E. G. Evagorou and R. Duncan, 1999, Dendrimer-platinate: a novel approach to cancer chemotherapy. Anticancer Drugs 10:767-776.
78. Huuskonen, J., 2001, Estimation of aqueous solubility in drug design. Comb Chem High Throughput Screen 4:311-316.
79. Alakhov, V., G. Pietrzynski and A. Kabanov, 2001, Combinatorial approaches to formulation development. Curr Opin Drug Discov Devel 4:493-501.
80. Wike-Hooley, J. L., J. Haveman and H. S. Reinhold, 1984, The relevance of tumour pH to the treatment of malignant disease. Radiother Oncol 2:343-366.
81. Solomatin, S. V., T. K. Bronich, V. A. Kabanov, A. Eisenberg and A. V. Kabanov, 2001, Block ionomer complexes: novel environmentally responsive materials. Polym. Prepr. 42:107-108.
82. Ponnappa, B. C., I. Dey, G. C. Tu, F. Zhou, M. Aini, Q. N. Cao and Y. Israel, 2001, In vivo delivery of antisense oligonucleotides in pH-sensitive liposomes inhibits lipopolysaccharide-induced production of tumor necrosis factor-alpha in rats. J Pharmacol Exp Ther 297:1129-1136.
83. Drummond, D. C., M. Zignani and J. Leroux, 2000, Current status of pH-sensitive liposomes in drug delivery. Prog Lipid Res 39:409-460.
84. Straubinger, R. M., N. Duzgunes and D. Papahadjopoulos, 1985, pH-sensitive liposomes mediate cytoplasmic delivery of encapsulated macromolecules. FEBS Lett 179:148-154.
85. Liu, D. and L. Huang, 1989, Role of cholesterol in the stability of pH-sensitive, large unilamellar liposomes prepared by the detergent-dialysis method. Biochim Biophys Acta 981:254-260.
86. Reddy, J. A. and P. S. Low, 2000, Enhanced folate receptor mediated gene therapy using a novel pH- sensitive lipid formulation. J Control Release 64:27-37.
87. Parente, R. A., L. Nadasdi, N. K. Subbarao and F. C. Szoka, Jr., 1990, Association of a pH-sensitive peptide with membrane vesicles: role of amino acid sequence. Biochemistry 29:8713-8719.
88. Ishida, T., M. J. Kirchmeier, E. H. Moase, S. Zalipsky and T. M. Allen, 2001, Targeted delivery and triggered release of liposomal doxorubicin enhances cytotoxicity against human B lymphoma cells. Biochim Biophys Acta 1515:144-158.
89. Meyer, O., D. Papahadjopoulos and J. C. Leroux, 1998, Copolymers of N-isopropylacrylamide can trigger pH sensitivity to stable liposomes. FEBS Lett 421:61-64.
90. Leroux, J., E. Roux, D. Le Garrec, K. Hong and D. C. Drummond, 2001, N-isopropylacrylamide copolymers for the preparation of pH-sensitive liposomes and polymeric micelles. J Control Release 72:71-84.
91. Kohori, F., K. Sakai, T. Aoyagi, M. Yokoyama, M. Yamato, Y. Sakurai and T. Okano, 1999, Control of adriamycin cytotoxic activity using thermally responsive polymeric micelles composed of poly(N-isopropylacrylamide-co-N,N-dimethylacrylamide)-b-poly(D,L-lactide). Colloids Surf., B: Biointerfaces 16:195-205.
92. Munshi, N., N. Rapoport and W. G. Pitt, 1997, Ultrasonic activated drug delivery from Pluronic P-105 micelles. Cancer Lett. 118:13-19.
93. Rapoport, N. Y., J. N. Herron, W. G. Pitt and L. Pitina, 1999, Micellar delivery of doxorubicin and its paramagnetic analog, ruboxyl, to HL-60 cells: effect of micelle structure and ultrasound on the intracellular drug uptake. J. Controlled Release 58:153-162.
94. Husseini, G., G. D. Myrup, W. G. Pitt, D. A. Christensen and N. Y. Rapoport, 2000, Factors affecting acoustically triggered release of drugs from polymeric micelles. J. Controlled Release 69:43-52.
95. Stayton, P. S., A. S. Hoffman, N. Murthy, C. Lackey, C. Cheung, P. Tan, L. A. Klumb, A. Chilkoti, F. S. Wilbur and O. W. Press, 2000, Molecular engineering of proteins and polymers for targeting and intracellular delivery of therapeutics. J Control Release 65:203-220.
96. Hoffman, A. S., P. S. Stayton, V. Bulmus, G. Chen, J. Chen, C. Cheung, A. Chilkoti, Z. Ding, L. Dong, R. Fong, C. A. Lackey, C. J. Long, M. Miura, J. E. Morris, N. Murthy, Y. Nabeshima, T. G. Park, O. W. Press, T. Shimoboji, S. Shoemaker, H. J. Yang, N. Monji, R. C. Nowinski, C. A. Cole, J. H. Priest, J. M. Harris, K. Nakamae, T. Nishino and T. Miyata, 2000, Founder's Award, Society for Biomaterials. Sixth World Biomaterials Congress 2000, Kamuela, HI, May 15-20, 2000. Really smart bioconjugates of smart polymers and receptor proteins. J Biomed Mater Res 52:577-586.
97. Hoffman, A. S., P. S. Stayton, V. Bulmus, G. Chen, J. Chen, C. Cheung, A. Chilkoti, Z. Ding, L. Dong, R. Fong, C. A. Lackey, C. J. Long, M. Miura, J. E. Morris, N. Murthy, Y. Nabeshima, T. G. Park, O. W. Press, T. Shimoboji, S. Shoemaker, H. J. Yang, N. Monji, R. C. Nowinski, C. A. Cole, J. H. Priest, J. M. Harris, K. Nakamae, T. Nishino and T. Miyata, 2000, Founder's Award, Society for Biomaterials. Sixth World Biomaterials Congress 2000, Kamuela, HI, May 15-20, 2000. Really smart bioconjugates of smart polymers and receptor proteins. J Biomed Mater Res 52:577-586.
98. Lackey, C. A., N. Murthy, O. W. Press, D. A. Tirrell, A. S. Hoffman and P. S. Stayton, 1999, Hemolytic activity of pH-responsive polymer-streptavidin bioconjugates. Bioconjug Chem 10:401-405.
99. Murthy, N., J. R. Robichaud, D. A. Tirrell, P. S. Stayton and A. S. Hoffman, 1999, The design and synthesis of polymers for eukaryotic membrane disruption. J Control Release 61:137-143.
100. Cheung, C. Y., N. Murthy, P. S. Stayton and A. S. Hoffman, 2001, A pH-sensitive polymer that enhances cationic lipid-mediated gene transfer. Bioconjug Chem 12:906-910.
101. Kyriakides, T. R., C. Y. Cheung, N. Murthy, P. Bornstein, P. S. Stayton and A. S. Hoffman, 2002, pH-sensitive polymers that enhance intracellular drug delivery in vivo. J Control Release 78:295-303.
102. Tachibana, R., H. Harashima, M. Shono, M. Azumano, M. Niwa, S. Futaki and H. Kiwada, 1998, Intracellular regulation of macromolecules using pH-sensitive liposomes and nuclear localization signal: qualitative and quantitative evaluation of intracellular trafficking. Biochem Biophys Res Commun 251:538-544.
103. Kabanov, A. V., A. V. Levashov and V. Y. Alakhov, 1989, Lipid modification of proteins and their membrane transport. Protein Eng. 3:39-42.
104. Kabanov, A. V., A. V. Ovcharenko, N. S. Melik-Hubarov, A. I. Bannikov, V. Alakhov, V. I. Kiselev, P. G. Sveshnikov, O. I. Kiselev, A. V. Levashov and E. S. Severin, 1989, Fatty acid acylated antibodies against virus suppress its reproduction in cells. FEBS Lett. 250:238-240.
105. Kabanov, A. V., V. Y. Alakhov and V. P. Chekhonin, 1992, Enhancement of macromolecule penetration into cells and nontraditional drug delivery systems, In, Harwood Academic Publishers, Glasgow pp 1-77.
106. Slepnev, V. I., L. Phalente, H. Labrousse, N. S. Melik-Nubarov, V. Mayau, B. Goud, G. Buttin and A. V. Kabanov, 1995, Fatty acid acylated peroxidase as a model for the study of interactions of hydrophobically-modified proteins with mammalian cells. Bioconjug. Chem. 6:608-615.
107. Alakhov, V., A. V. Kabanov, E. V. Batrakova, I. A. Koromyslova, A. V. Levashov and E. S. Severin, 1990, Increasing cytostatic effects of ricin A chain and Staphylococcus aureus enterotoxin A through in vitro hydrophobization with fatty acid residues. Biotechnol. Appl. Biochem. 12:94-98.
108. Oda, T. and H. Maeda, 1987, Binding to and internalization by cultured cells of neocarzinostatin and enhancement of its actions by conjugation with lipophilic styrenemaleic acid copolymer. Cancer Res 47:3206-3211.
109. Oda, T., F. Sato and H. Maeda, 1987, Facilitated internalization of neocarzinostatin and its lipophilic polymer conjugate, SMANCS, into cytosol in acidic pH. J Natl Cancer Inst 79:1205-1211.
110. Slepnev, V. P., 1992, Modification of proteins for transport of biologically active compounds within the cell, Dissertation, Moscow State University.
111. Gebhart, C. L., S. Sriadibhatla, S. Vinogradov and A. Kabanov, 2001, Pluronic-polyethyleneimine conjugates for gene delivery. Polym. Prepr. (Am. Chem. Soc., Div. Polym. Chem.) 42:119-120.
112. Batrakova, E. V., S. Li, S. V. Vinogradov, V. Y. Alakhov, D. W. Miller and A. V. Kabanov, 2001, Mechanism of pluronic effect on p-glycoprotein efflux system in blood brain barrier: contributions of energy depletion and membrane fluidization. J. Pharmacol. Exp. Ther. 299:483-493.
113. Snyder, E. L. and S. F. Dowdy, 2001, Protein/peptide transduction domains: potential to deliver large DNA molecules into cells. Curr Opin Mol Ther 3:147-152.
114. Schwartz, J. J. and S. Zhang, 2000, Peptide-mediated cellular delivery. Curr Opin Mol Ther 2:162-167.
115. Torchilin, V. P., R. Rammohan, V. Weissig and T. S. Levchenko, 2001, TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. Proc Natl Acad Sci U S A 98:8786-8791.
116. Ambudkar, S. V., S. Dey, C. A. Hrycyna, M. Ramachandra, I. Pastan and M. M. Gottesman, 1999, Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Ann. Rev. Pharmacol. Toxicol. 39:361-398.
117. Zhang, Y., H. Han, W. F. Elmquist and D. W. Miller, 2000, Expression of various multidrug resistance-associated protein (MRP) homologues in brain microvessel endothelial cells. Brain Res. 876:148-153.
118. Naito, S., A. Yokomizo and H. Koga, 1999, Mechanisms of drug resistance in chemotherapy for urogenital carcinoma. Int. J. Urol. 6:427-439.
119. Nooter, K. and G. Stoter, 1996, Molecular mechanisms of multidrug resistance in cancer chemotherapy. Pathol. Res. Pract. 192:768-780.
120. Minko, T., P. Kopeckova, V. Pozharov and J. Kopecek, 1998, HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line. J Control Release 54:223-233.
121. Minko, T., P. Kopeckova and J. Kopecek, 1999, Chronic exposure to HPMA copolymer-bound adriamycin does not induce multidrug resistance in a human ovarian carcinoma cell line. J Control Release 59:133-148.
122. Tijerina, M., K. D. Fowers, P. Kopeckova and J. Kopecek, 2000, Chronic exposure of human ovarian carcinoma cells to free or HPMA copolymer-bound mesochlorin e6 does not induce P-glycoprotein-mediated multidrug resistance. Biomaterials 21:2203-2210.
123. Omelyanenko, V., P. Kopeckova, C. Gentry and J. Kopecek, 1998, Targetable HPMA copolymer-adriamycin conjugates. Recognition, internalization, and subcellular fate. J Control Release 53:25-37.
124. Miyamoto, Y., T. Oda and H. Maeda, 1990, Comparison of the cytotoxic effects of the high- and low-molecular- weight anticancer agents on multidrug-resistant Chinese hamster ovary cells in vitro. Cancer Res 50:1571-1575.
125. Minko, T., P. Kopeckova and J. Kopecek, 2001, Preliminary evaluation of caspases-dependent apoptosis signaling pathways of free and HPMA copolymer-bound doxorubicin in human ovarian carcinoma cells. J Control Release 71:227-237.
126. Batrakova, E. V., S. Li, W. F. Elmquist, D. W. Miller, V. Y. Alakhov and A. V. Kabanov, 2001, Mechanism of sensitization of MDR cancer cells by Pluronic block copolymers: selective energy depletion. Br. J. Cancer 85:1987-1997.
127. Alakhov, V. Y., E. Y. Moskaleva, E. V. Batrakova and A. V. Kabanov, 1996, Hypersensitization of multidrug resistant human ovarian carcinoma cells by pluronic P85 block copolymer. Bioconjug. Chem. 7:209-216.
128. Batrakova, E. V., S. Li, D. W. Miller and A. V. Kabanov, 1999, Pluronic P85 increases permeability of a broad spectrum of drugs in polarized BBMEC and Caco-2 cell monolayers. Pharm. Res. 16:1366-1372.
129. Venne, A., S. Li, R. Mandeville, A. Kabanov and V. Alakhov, 1996, Hypersensitizing effect of pluronic L61 on cytotoxic activity, transport, and subcellular distribution of doxorubicin in multiple drug- resistant cells. Cancer Res. 56:3626-3629.
130. Pifferi, G., P. Santoro and M. Pedrani, 1999, Quality and functionality of excipients. Farmaco 54:1-14.
131. Bomford, R., 1981, The adjuvant activity of fatty acid esters. The role of acyl chain length and degree of saturation. Immunology 44:187-192.
132. Hunter, R., M. Olsen and S. Buynitzky, 1991, Adjuvant activity of non-ionic block copolymers. IV. Effect of molecular weight and formulation on titre and isotype of antibody. Vaccine 9:250-256.
133. Hunter, R., F. Strickland and F. Kezdy, 1981, The adjuvant activity of nonionic block polymer surfactants. I. The role of hydrophile-lipophile balance. J. Immunol. 127:1244-1250.
134. Hunter, R. L. and B. Bennett, 1984, The adjuvant activity of nonionic block polymer surfactants. II. Antibody formation and inflammation related to the structure of triblock and octablock copolymers. J. Immunol. 133:3167-3175.
135. Hunter, R. L. and B. Bennett, 1986, The adjuvant activity of nonionic block polymer surfactants. III. Characterization of selected biologically active surfaces. Scand. J. Immunol. 23:287-300.
136. Hunter, R. L., J. McNicholl and A. A. Lal, 1994, Mechanisms of action of nonionic block copolymer adjuvants. AIDS Res Hum Retroviruses 10:S95-S98.
137. Allison, A. C. and N. E. Byars, 1986, An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity. J. Immunol. Methods 95:157-168.
138. Allison, A. C. and N. E. Byars, 1990, Adjuvant formulations and their mode of action. Semin. Immunol. 2:369-374.
139. Ke, Y., C. L. McGraw, R. L. Hunter and J. A. Kapp, 1997, Nonionic triblock copolymers facilitate delivery of exogenous proteins into the MHC class I and class II processing pathways. Cell Immunol. 176:113-121.
140. Millet, P., M. L. Kalish, W. E. Collins and R. L. Hunter, 1992, Effect of adjuvant formulations on the selection of B-cell epitopes expressed by a malaria peptide vaccine. Vaccine 10:547-550.
141. Takayama, K., M. Olsen, P. Datta and R. L. Hunter, 1991, Adjuvant activity of non-ionic block copolymers. V. Modulation of antibody isotype by lipopolysaccharides, lipid A and precursors. Vaccine 9:257-265.
142. Schmolka, I. R., 1972, Artificial skin. I. Preparation and properties of pluronic F-127 gels for treatment of burns. J. Biomed. Mater. Res. 6:571-582.
143. Rodeheaver, G., V. Turnbull, M. T. Edgerton, L. Kurtz and R. F. Edlich, 1976, Pharmacokinetics of a new skin wound cleanser. Am. J. Surg. 132:67-74.
144. Rodeheaver, G. T., L. Kurtz, B. J. Kircher and R. F. Edlich, 1980, Pluronic F-68: a promising new skin wound cleanser. Ann. Emerg. Med. 9:572-576.
145. Nalbandian, R. M., R. L. Henry, K. W. Balko, D. V. Adams and N. R. Neuman, 1987, Pluronic F-127 gel preparation as an artificial skin in the treatment of third-degree burns in pigs. J. Biomed. Mater. Res. 21:1135-1148.
146. Gear, A. J., T. B. Hellewell, H. R. Wright, P. M. Mazzarese, P. B. Arnold, G. T. Rodeheaver and R. F. Edlich, 1997, A new silver sulfadiazine water soluble gel. Burns 23:387-391.
147. Follis, F., B. Jenson, K. Blisard, E. Hall, R. Wong, R. Kessler, T. Temes and J. Wernly, 1996, Role of poloxamer 188 during recovery from ischemic spinal cord injury: a preliminary study. J. Invest. Surg. 9:149-156.
148. Agren, M. S., 1998, An amorphous hydrogel enhances epithelialisation of wounds. Acta Derm. Venereol. 78:119-122.
149. Cao, Y. L., E. Lach, T. H. Kim, A. Rodriguez, C. A. Arevalo and C. A. Vacanti, 1998, Tissue-engineered nipple reconstruction. Plast. Reconstr. Surg. 102:2293-2298.
150. Vlahos, A., P. Yu, C. E. Lucas and A. M. Ledgerwood, 2001, Effect of a composite membrane of chitosan and poloxamer gel on postoperative adhesive interactions. Am. Surg. 67:15-21.
151. Leach, R. E. and R. L. Henry, 1990, Reduction of postoperative adhesions in the rat uterine horn model with poloxamer 407. Am. J. Obstet. Gynecol. 162:1317-1319.
152. Hannig, J., D. Zhang, D. J. Canaday, M. A. Beckett, R. D. Astumian, R. R. Weichselbaum and R. C. Lee, 2000, Surfactant sealing of membranes permeabilized by ionizing radiation. Radiat. Res. 154:171-177.
153. Lee, R. C., D. J. Canaday and S. M. Hammer, 1993, Transient and stable ionic permeabilization of isolated skeletal muscle cells after electrical shock. J. Burn. Care Rehabil. 14:528-540.
154. Lee, R. C., J. Hannig, K. L. Matthews, A. Myerov and C. T. Chen, 1999, Pharmaceutical therapies for sealing of permeabilized cell membranes in electrical injuries. Ann. NY Acad. Sci. 888:266-273.
155. Batrakova, E. V., S. Li, V. Y. Alakhov and A. V. Kabanov, 2000, Selective energy depletion and sensitization of multiple drug resistant cancer cells by Pluronic block copolymers. Polym. Prepr. 41:1639-1640.
156. Batrakova, E. V., S. Lee, S. Li, A. Venne, V. Alakhov and A. Kabanov, 1999, Fundamental relationships between the composition of pluronic block copolymers and their hypersensitization effect in MDR cancer cells. Pharm. Res. 16:1373-1379.
157. Demoy, M., T. Minko, P. Kopeckova and J. Kopecek, 2000, Time- and concentration-dependent apoptosis and necrosis induced by free and HPMA copolymer-bound doxorubicin in human ovarian carcinoma cells. J Control Release 69:185-196.
158. Keatley, K. L., 1999, A review of US EPA and FDA requirements for electronic records, electronic signatures, and electronic submissions. Qual Assur 7:77-89.
159. Nishi, H., 1999, Capillary electrophoresis of drugs: current status in the analysis of pharmaceuticals. Electrophoresis 20:3237-3258.
160. Kabanov, A. V., I. R. Nazarova, I. V. Astafieva, E. V. Batrakova, V. Y. Alakhov, A. A. Yaroslavov and V. A. Kabanov, 1995, Micelle formation and solubilization of fluorescent probes in poly(oxyethylene-b-oxypropylene-b-oxyethylene) solutions. Macromolecules 28:2303-2314.